Table 1 Baseline characteristics and treatment patterns for IMPC and IDC
IMPC (n = 33) | IDC (n = 347) | P* | |
|---|---|---|---|
Age (year) | 0.885 | ||
≤45 | 11 (33.3 %) | 120 (34.6 %) | |
>45 | 22 (66.7 %) | 227 (65.4 %) | |
Family history | 0.179 | ||
Yes | 2 (6.1 %) | 7 (2.0 %) | |
No | 17 (21.5 %) | 340 (98.0 %) | |
ER status | 0.011 | ||
Positive | 27 (81.8 %) | 206 (59.4 %) | |
Negative | 6 (18.2 %) | 141 (40.6 %) | |
PR status | 0.123 | ||
Positive | 25 (75.8 %) | 209 (62.6 %) | |
Negative | 8 (24.2 %) | 125 (37.4 %) | |
Her2 status | 0.479 | ||
Positive | 6 (18.8 %) | 82 (24.3 %) | |
Negative | 26 (81.2 %) | 255 (75.7 %) | |
Unknown | 1 | 10 | |
Subtype | 0.006 | ||
Luminal | 29 (87.9 %) | 223 (64.3 %) | |
Non-luminal | 4 (12.1 %) | 124 (35.7 %) | |
T classification | 0.044 | ||
T1–T2 | 25 (75.8 %) | 309 (89.0 %) | |
T3–T4 | 8 (24.2 %) | 38 (11.0 %) | |
N classification | <0.001 | ||
N0 | 7 (21.2 %) | 186 (53.8 %) | |
N1–N3 | 26 (78.2 %) | 160 (46.2 %) | |
Unknown | 0 | 1 | |
Staging | <0.001 | ||
I–II | 15 (45.5 %) | 262 (76.2 %) | |
III | 18 (54.5 %) | 82 (23.8 %) | |
Unknown | 0 | 3 | |
Operation methods | 0.392 | ||
BCS | 0 (0 %) | 19 (5.5 %) | |
Mastectomy | 33 (100 %) | 328 (94.5 %) | |
Adjuvant chemotherapy | 0.709 | ||
Yes | 32 (97 %) | 321 (93.3 %) | |
No | 1 (3.0 %) | 23 (6.7 %) | |
Unknown | 0 | 3 | |
Radiotherapy | 0.146 | ||
Yes | 14 (42.4 %) | 104 (30.1 %) | |
No | 19 (57.6 %) | 241 (69.9 %) | |
Unknown | 0 | 2 | |
Hormone therapy | 0.026 | ||
Yes | 28 (84.8 %) | 227 (65.8 %) | |
No | 5 (15.2 %) | 118 (34.2 %) | |
Unknown | 0 | 2 | |
Neoadjuvant chemotherapy | 0.128 | ||
Yes | 4 (12.1 %) | 19 (5.5 %) | |
No | 29 (87.9 %) | 328 (94.5 %) | |
Trastuzumab | 0.754 | ||
Yes | 2 (6.1 %) | 33 (9.5 %) | |
No | 31 (93.9 %) | 314 (90.5 %) | |
Lymphovascular invasion | <0.001 | ||
Yes | 6 (18.2 %) | 2 (0.6 %) | |
No | 27 (81.8 %) | 345 (99.4 %) | |
Nerve invasion | 0.007 | ||
Yes | 2 (6.1 %) | 0 (0 %) | |
No | 3193.9 %) | 347 (100 %) | |